The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

被引:641
|
作者
Younossi, Zobair M. [1 ,2 ,3 ]
Golabi, Pegah [1 ,2 ,3 ]
Paik, James M. [1 ,2 ,3 ]
Henry, Austin [1 ]
Van Dongen, Catherine [1 ]
Henry, Linda [1 ,2 ,3 ]
机构
[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA
[2] Inova Fairfax Med Campus, Ctr Liver Dis, Dept Med, Falls Church, VA USA
[3] Inova Hlth Syst, Inova Med, Falls Church, VA USA
关键词
PREVALENCE; METAANALYSIS; REGRESSION; BURDEN; UPDATE; BIAS;
D O I
10.1097/HEP.0000000000000004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. Approach and Results: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Meta-analysis was conducted using randomeffects models. Bias risk assessment was per Joanna Briggs Institute. Of 2585 studies reviewed, 92 studies (N = 9,361,716) met eligibility criteria. Across the study period (1990-2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%-32.32%) and 30.69% (28.4-33.09), respectively. Global NAFLD prevalence increased by +50.4% from 25.26% (21.59-29.33) in 1990-2006 to 38.00% (33.71-42.49) in 2016-2019 (p<0.001); ultrasound-defined NAFLD prevalence increased by +38.7% from 25.16% (19.46-31.87) in 1990-2006 to 34.59% (29.05-40.57) (p = 0.029). The highest NAFLD prevalence was in Latin America 44.37% (30.66%-59.00%), then Middle East and North Africa (MENA) (36.53%, 28.63%-45.22%), South Asia (33.83%, 22.91%-46.79%), South-East Asia (33.07%, 18.99%-51.03%), North America (31.20%, 25.86%-37.08%), East Asia (29.71%, 25.96%-33.76%), Asia Pacific 28.02% (24.69%-31.60%), Western Europe 25.10% (20.55%-30.28%). Among the NAFLD cohort diagnosed without a liver biopsy, pooled mortality rate per 1000 PY was 12.60 (6.68-23.67) for all-cause mortality; 4.20 (1.34-7.05) for cardiac-specific mortality; 2.83 (0.78-4.88) for extrahepatic cancer-specific mortality; and 0.92 (0.00-2.21) for liver-specific mortality. Conclusions: NAFLD global prevalence is 30% and increasing which requires urgent and comprehensive strategies to raise awareness and address all aspects of NAFLD on local, regional, and global levels.
引用
收藏
页码:1335 / 1347
页数:13
相关论文
共 50 条
  • [1] Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
    Duarte, Sebastiao M. B.
    Stefano, Jose Tadeu
    Oliveira, Claudia P.
    [J]. ANNALS OF HEPATOLOGY, 2019, 18 (03) : 416 - 421
  • [2] Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH)
    Ota, Tsuguhito
    [J]. CAROTENOIDS: BIOSYNTHETIC AND BIOFUNCTIONAL APPROACHES, 2021, 1261 : 223 - 229
  • [3] Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
    Drescher, Hannah K.
    Weiskirchen, Sabine
    Weiskirchen, Ralf
    [J]. CELLS, 2019, 8 (08)
  • [4] Predictive Factors for Nonalcoholic Steatohepatitis (NASH) in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
    Fierbinteanu-Braticevici, Carmen
    Baicus, Cristian
    Tribus, Laura
    Papacocea, Raluca
    [J]. JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2011, 20 (02) : 153 - 159
  • [5] Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in Patients with Morbid Obesity
    Manno, Emilio
    [J]. OBESITY SURGERY, 2010, 20 (06) : 811 - 811
  • [6] Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)
    Gerhardt, Florian
    Petroff, David
    Blank, Valentin
    Boehlig, Albrecht
    van Boemmel, Florian
    Wittekind, Christian
    Berg, Thomas
    Karlas, Thomas
    Wiegand, Johannes
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 706 - 711
  • [7] Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis
    Zhu, Yuezhi
    Tan, Jen Kit
    Wong, Sok Kuan
    Goon, Jo Aan
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (11)
  • [8] Vitamin D deficiency and development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
    Bril, Fernando
    Lomonaco, Romina
    Orsak, Beverly
    Ortiz-Lopez, Carolina
    Biernacki, Diane
    Klaczak, Ashley
    Chang, Zhi
    Hardies, Jean
    Cusi, Kenneth
    [J]. HEPATOLOGY, 2013, 58 : 522A - 522A
  • [9] Variants of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with rapidly progressive course
    Tan, V.
    Merriman, R.
    Ferrell, L.
    [J]. LABORATORY INVESTIGATION, 2008, 88 : 317A - 317A
  • [10] Variants of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with rapidly progressive course
    Tan, V.
    Jimenez, C.
    Merriman, R.
    Ferrell, L.
    [J]. MODERN PATHOLOGY, 2008, 21 : 317A - 317A